Skip to main content

Advertisement

SpringerLink
Log in

Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Dopamine agonists (DA) are the mainstay of treatment for patients with prolactinomas. To describe the efficacy of treatment and the outcomes of DA withdrawal. Retrospective review of electronic medical records of patients with prolactinomas from 1985 to 2009. Seventy-nine patients (17 men/62 women), aged 35.3 ± 1.6 years at diagnosis were studied. The mean follow-up time was 84.7 ± 9.2 months (range 0–336). The mean initial size of microadenomas was 0.74 ± 0.10 cm (range 2.41 ± 0.39) and of macrodenomas 2.41 ± 0.39 cm (range 1.1–8) and serum prolactin (PRL) levels were 112 ± 19 and 263 ± 59 ng/ml, respectively (normal range 0–40). Fifty-one (65%) prolactinomas were micro- and 28 (35%) were macroadenomas. DA led to a decrease in adenoma size in 71% of them, while 53% of microadenomas were not visible during follow-up. In 26 patients, DA withdrawal was decided. After therapy of >24 months and a mean follow-up time of 49 ± 11 months (range 3–168), 15 subjects (58%) showed no recurrence of hyperprolactinemia. Higher remission rates, although not statistically significant, were observed with cabergoline (75%). The mean PRL levels before DA discontinuation were 12.2 ± 2.3 ng/ml (range 0.5–44.7) and after discontinuation they were significantly lower than pre-treatment values. Recurrence of hypeprolactinemia was evident during the first year in all but one patient. Remission rates were not associated with age or size of adenoma at diagnosis, initial or before DA discontinuation PRL levels and duration of treatment. DA withdrawal was followed by remission of hyperprolactinamia in about half of patients after >2 years of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265–273

    Article  Google Scholar 

  2. Kars M, Dekkers OM, Pereira AM, Romijn JA (2010) Update in prolactinomas. Neth J Med 68:104–112

    PubMed  CAS  Google Scholar 

  3. Acquati S, Pizzocaro A, Tomei G, Giovanelli M, Libè R, Faglia G, Ambrosi B (2001) A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma. J Neurosurg Sci 45:65–69

    PubMed  CAS  Google Scholar 

  4. Nomikos P, Buchfelder M, Fahbusch R (2001) Current management of prolactinomas. J Neurooncol 54:139–150

    Article  PubMed  CAS  Google Scholar 

  5. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522

    Article  PubMed  CAS  Google Scholar 

  6. Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94:2428–2436

    Article  PubMed  CAS  Google Scholar 

  7. Cannavò S, Curtò L, Squadrito S, Almoto B, Vieni A, Trimarchi F (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22:354–359

    PubMed  Google Scholar 

  8. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574–3579

    Article  PubMed  CAS  Google Scholar 

  9. Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet 2:187–192

    Article  PubMed  CAS  Google Scholar 

  10. Maxson WS, Dudzinski M, Handwerger SH, Hammond CB (1984) Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertil Steril 41:218–223

    PubMed  CAS  Google Scholar 

  11. van ‘t Verlaat JW, Croughs RJ (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 34:175–178

    Article  Google Scholar 

  12. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20:537–546

    PubMed  CAS  Google Scholar 

  13. Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D’Alberton A, Crosignani P (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 126:489–494

    CAS  Google Scholar 

  14. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63:26–31

    Article  CAS  Google Scholar 

  15. Passos VQ, Souza JJ, Musolino NR, Bronstein MD (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87:3578–3582

    Article  PubMed  CAS  Google Scholar 

  16. Rasmussen C, Bergh T, Wide L (1987) Prolactin secretion and menstrual function after long-term bromocriptine treatment. Fertil Steril 48:550–554

    PubMed  CAS  Google Scholar 

  17. Huda MS, Athauda NB, Teh MM, Carroll PV, Powrie JK (2010) Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol (Oxf) 72:507–511

    Article  CAS  Google Scholar 

  18. Colao A, Di Sarno A, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033

    Article  PubMed  CAS  Google Scholar 

  19. Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi G (2007) Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 67:426–433

    Article  CAS  Google Scholar 

  20. Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95:43–51

    Article  PubMed  CAS  Google Scholar 

  21. Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53:53–60

    Article  CAS  Google Scholar 

Download references

Conflict of interest

The authors have no conflict of interest pertinent to this manuscript.

Author information

Authors and Affiliations

  1. Endocrinology Clinic, Hippokration Hospital, 49 Konstantinoupoleos Str, 54 642, Thessaloniki, Greece

    Panagiotis Anagnostis, Fotini Adamidou, Stergios A. Polyzos, Zoe Efstathiadou, Eleni Karathanassi & Marina Kita

Authors
  1. Panagiotis Anagnostis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fotini Adamidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stergios A. Polyzos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zoe Efstathiadou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eleni Karathanassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marina Kita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Panagiotis Anagnostis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anagnostis, P., Adamidou, F., Polyzos, S.A. et al. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary 15, 25–29 (2012). https://doi.org/10.1007/s11102-011-0303-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-011-0303-6

Keywords

Search

Navigation